Abstract. Interleukin (IL)-17 signaling serves an important role in the development and pathogenesis of psoriasis; a chronic skin disease characterized by increased dermal vascularity and the hyperproliferation of keratinocytes. microRNA (miR)-203 is preferentially expressed in the skin and is an important regulator of keratinocyte differentiation. miR-203 has been implicated in a number of skin diseases, including psoriasis. However, the role of miR-203 in IL-17-induced vascular endothelial growth factor (VEGF) secretion has yet to be elucidated. The present study demonstrated that miR-203 expression was upregulated in the ears of IL-17-stimulated mice and IL-17-treated HaCaT cells. In addition, the IL-17-induced increase in miR-203 expression activated the Janus kinase/signal transducer and activator of transcription signaling pathway and promoted VEGF secretion in HaCaT cells. Furthermore, miR-203 was observed to bind to the 3'-untranslated region of suppressor of cytokine signaling 3 (SOCS3) and inhibited SOCS3 expression. The results suggest that miR-203 expression may be upregulated by IL-17 stimulation, and miR-203 is a positive regulator of IL-17-induced VEGF secretion. The present study may support potential therapeutic strategies for the treatment of psoriasis.
Introduction
Psoriasis is a complex skin disease involving reciprocity between immune cells and keratinocytes, and is characterized by the infiltration of multiple inflammatory cells, upregulation dermal vascularity and keratinocyte proliferation (1) (2) (3) (4) . Angiogenesis commences with early psoriatic alterations and disappears when the disease is cured. A number of pro-angiogenic mediators, including vascular endothelial growth factor (VEGF), tumor necrosis factor, hypoxia-inducible factor, interleukin (IL)-8, angiopoietins and IL-17, are upregulated during the development of psoriasis (5) (6) (7) (8) .
Initially, psoriasis was considered to be a T-helper (Th)1-mediated skin disease (9) . However, a number of subsequent studies later demonstrated that Th17 cells, which are activated upon exposure to IL-23, IL-6 and transforming growth factor-β and produce IL-17, IL-21 and IL-22 cytokines, serves a key role in the pathogenesis of psoriasis (9) (10) (11) (12) . IL-17 is one of the most potent proinflammatory cytokines, and is secreted by Th17 cells (9) . A previous study indicated that IL-17 may induce keratinocytes to produce VEGF, which is an important angiogenic mediator (13) . Therefore, elucidation of the mechanisms by which IL-17 signaling in keratinocytes is regulated may facilitate the development of novel treatments for Th17-mediated angiogenesis.
The Janus kinase/signal transducer and activator of transcription signaling (JAK/STAT) signaling pathway controls a number of important biological responses, including cellular differentiation, immune functions, hematopoiesis and cellular growth, and it is initiated when a receptor is bound by its corresponding cytokine and subsequently transmits signals from the cell surface membrane to the target genes (14) . A previous study confirmed that IL-17 induced upregulation of VEGF expression via activation of the JAK2/STAT3 signaling pathway (15) . However, the precise mechanisms involved required further investigation. An increasing number of studies have indicated that microRNAs (miRNAs/miRs) may be involved in the pathogenesis of psoriasis, and miRNAs associated with psoriasis have been identified by comparing their expression in normal and psoriatic skin samples (16, 17) . However, whether specific miRNAs influence the process of IL-17-induced VEGF expression remains unclear.
miR-203 is preferentially expressed in the skin and is an important regulator of keratinocyte differentiation. miR-203 has been implicated in a number of skin diseases, particularly psoriasis (18) . However, the role of miR-203 in IL-17-induced VEGF secretion has yet to be elucidated. The aim of the present study was to investigate the role of miR-203 in IL-17-induced VEGF secretion to further elucidate the mechanism of miR-203 in psoriasis. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The mice were injected intradermally into each ear with 30 µl PBS, either alone or with 3 µg recombinant mouse IL-17A once a day for two consecutive days. Following 1 week, the ear tissues were collected and the expression of miR-203a-3p.1 in ear tissues was determined by RT-qPCR. Total RNA from ear tissues was extracted using TRIzol (Takara Biotechnology Co., Ltd., Dalian, China) following the manufacturer's instructions. Single strand cDNA was synthesized using the PrimeScript miRNA cDNA Synthesis kit (Takara Biotechnology Co., Ltd.) using 2 µg of total RNA as a template according to the manufacturer's instructions. qPCR was performed using SYBR Premix Ex Taq (Takara Biotechnology Co., Ltd.) according to the manufacturer's instructions. The thermocycling conditions were as follows:
95˚C for 30 sec, followed by 45 cycles of 95˚C for 5 sec and 53˚C for 20 sec. The expression of U6 small nuclear B non-coding RNA was used as an internal normalization control. The primers used were as follows: miR-203a-3p.1 primer, 5'-TAC GAG TGA AAT GTT TAG GAC CAC TAG-3'; U6, 5'-ATT GGA ACG ATA CAG AGA AGATT-3'.
HaCaT cells were treated with medium only or with IL-17 for 48 h, in the presence or absence of miR-203 inhibitor for 24 h. The expression of suppressor of cytokine signaling 3 (SOCS3) in HaCaT cells was then determined by RT-qPCR. cDNA was synthesized using the PrimeScript RT-PCR kit (Takara Biotechnology Co., Ltd.) using 2 µg of total RNA as a template according to the manufacturer's instructions. qPCR was performed using SYBR Premix Ex Taq (Takara Biotechnology Co., Ltd.) according to the manufacturer's instructions. The following thermocycling conditions were used: 95˚C for 30 sec, followed by 45 cycles of 95˚C for 5 sec and 60˚C for 20 sec. β-actin was used to normalize the expression levels of SOCS3. The primers used were as follows: SOCS3 forward, 5'-TGG ATG GAG CGG GAG GCT-3' , and reverse, 5'-ACG GAC ATC TTT CAC CTC AGG CTCCT-3'; β-actin forward, 5'-GAC AGG ATG CAG AAG GAG ATT ACT-3' and reverse, 5'-TGA TCC ACA TCT GCT GGA AGGT-3'. All RT-qPCR experiments were performed in triplicate using the Applied Biosystems 7500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). All primers were synthesized by Guangzhou RiboBio Co., Ltd. (Guangzhou, China). Samples were analyzed in triplicate, and the mean quantification cycle (C q ) was calculated. Gene expression levels were analyzed by comparing the ΔC q values of samples [where ΔC q =C q (target gene) -C q (housekeeping gene) ] transformed to a linear scale (2 -ΔΔCq ) (20) .
Cell culture. The human umbilical vein endothelial cells (HUVECs) cell line was purchased from the American Type Culture Collection (ATTC; Manassas, VA, USA). Cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (both from Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin, and maintained in a humidified atmosphere of 5% CO 2 at 37˚C. The human keratinocyte cell lines, HaCaT and HEK293T (both from ATCC), were incubated in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (both from Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin, and maintained in a humidified atmosphere of 5% CO 2 at 37˚C. inhibitor, 5'-CUA GUG GUC CUA AAC AUU UCAC-3'; miR-203a-3p.1 inhibitor control, 5'-CAG UAC UUU UGU GUA GUA CAA-3'. HaCaT cells were co-transfected with 150 nmol SOCS3 small interfering (si)RNA or scrambled siRNA (Shanghai GenePharma Co., Ltd., Shanghai, China) and 150 nmol miR-203 inhibitor using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen; Thermo Fisher Scientific, Inc.). At 24 h following transfection, HaCaT cells were treated with 80 ng/ml IL-17 (PeproTech, Inc., Rocky Hill, NJ, USA) for 48 h at 37˚C, then cells (~1.5x10 6 /well) were harvested for analysis. HUVECs were treated with conditioned HaCaT cell medium only at 37˚C for 7 h.
Luciferase reporter assays. For luciferase activity analysis, the 3'-UTR sequence of SOCS3 or the mutant SOCS3 3'-UTR sequence, which included a mutation in the miR-203 binding site, was cloned into a pGL3-promoter vector (Promega Corporation, Madison, WI, USA). Then HEK293T cells were co-transfected with 500 ng wild-type pGL3-SOCS3-3'UTR or mutant pGL3-SOCS3-3'UTR and 10 pmol miR-203 mimic or 10 pmol miRNA control using Lipofectamine 2000, according to the manufacturer's instructions (Invitrogen; Thermo Fisher Scientific, Inc.). At 24 h following transfection, luciferase activity was detected using a dual-luciferase reporter assay system according to the manufacturer's instructions (Promega Corporation). Luciferase activity was normalized to Renilla luciferase activity.
Computational prediction. The target gene of miR-203 was predicted using TargetScan Release 7.1 software (www.targetscan.org/vert_71/).
Western blot analysis.
HaCaT cells treated with medium alone or with IL-17 for 48 h, in the presence or absence of miR-203 inhibitor for 24 h. Total protein was extracted using a protein extraction kit (Beyotime Institute of Biotechnology, Haimen, China) according to the manufacturer's protocol. Protein concentration was determined using a bicinchoninic protein assay kit (Beyotime Institute of Biotechnology). For western blotting analysis, an equal quantity of total protein (30 µg/lane) was loaded, and separated by 8% SDS-PAGE. Following electrophoresis, proteins were transferred to a polyvinylidene difluoride membrane and blocked for 1 h at room temperature with 5% milk in TBS with 0.1% Tween-20. The membrane was incubated with primary antibodies against the IL-17 receptor (cat no. ab180904; 1:1,000 dilution; Abcam), phosphorylated (p)-JAK2 (cat no. 4406; 1:1,000 dilution), p-STAT3 (cat no. 9145; 1:1,000 dilution), β-actin (cat no. 4970; 1:1,000 dilution), SOCS1 (cat no. 3950; 1:1,000 dilution) and SOCS3 (cat no. 2932; 1:1,000 dilution) (all from Cell Signaling Technology, Inc., Danvers, MA, USA) at 4˚C overnight. The blots were subsequently incubated with a with horseradish peroxidase-conjugated secondary antibody (cat no. E030120-02; 1:2,000 dilution; EarthOx Life Sciences, Millbrae, CA, USA) for 1 h at room temperature. Proteins were visualized using Clarity Western ECL Substrate (Bio-Rad Laboratories, Inc., Hercules, CA, USA) according to the manufacturer's protocol. Densitometry analysis of the western blots was achieved using ImageJ v1.48 software (National Institutes of Health, Bethesda, MD, USA).
Tube formation assay. The tube formation assay was performed as described previously (21) . Briefly, a 96-well plate was coated with 60 µl Matrigel (BD Biosciences, Franklin Lakes, NJ, USA), which was allowed to polymerize and solidify at 37˚C for 30 min. HUVECs (2x10 4 cells) were seeded onto the Matrigel layer in the presence or absence of conditioned medium from HaCaT cells treated with IL-17 (80 ng/ml for 48 h), miR-203 inhibitor (150 nmol for 24 h) or inhibitor control (150 nmol for 24 h), and SOCS3-siRNA (150 nmol for 24 h) or siRNA-control (150 nmol for 24 h), and cells were incubated at 37˚C for 7 h. The number of blood-vessel-like tubules from six fields of view selected at random were counted, and images were captured using an inverted light microscope (Nikon Corporation, Tokyo, Japan).
Enzyme-linked immunosorbent assay (ELISA)
). The cell culture media were centrifuged at 1,500 x g for 10 min at 4˚C, the supernatants were collected and and stored at -80˚C prior to ELISA analysis. The level of VEGF secretion in HaCaT cell cultures were measured by an ELISA kit (cat no. DVE00; R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
Statistical analysis. Statistical analysis was performed using SPSS v13.0 software (SPSS, Inc., Chicago, IL, USA). The results were analyzed by one-way analysis of variance followed by a Student-Newman-Keuls post hoc test, and presented as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference. All experiments were repeated three times. (Fig. 1A-C) . The expression of miR-203 and VEGF secretion in IL-17-stimulated HaCaT cells was then investigated. Consistent with the in vivo results, miR-203 expression and VEGF secretion levels were significantly increased in HaCaT cells stimulated with IL-17 ( Fig. 1D and E) . (Fig. 2B and C) . In addition, the effect of miR-203 on IL-17-induced VEGF secretion was assessed using a tube formation assay in HUVECs. (Fig. 2B-E) . (Fig. 3A and B) . The next aim was to identify targets of miR-203. As demonstrated in (Fig. 3C-E) , the mRNA and protein expression levels of SOCS3, an inhibitor of the JAK2/STAT3 signaling pathway, was significantly upregulated in miR-203 inhibitor-transfected cells when compared with IL-17-stimulated and inhibitor control-transfected cells. By contrast, western blot analysis demonstrated that the protein expression levels of SOCS1, an additional inhibitor of the JAK2/STAT3 signaling pathway, were not significantly affected by miR-203 inhibition ( Fig. 3D and E) . These results suggest that miR-203 may inhibit JAK2/STAT3 signaling via targeting of SOCS3 expression.
Results

miR-203 is upregulated in the ears
Repression of miR-203 inhibits IL-17-induced activation
miR-203 directly targets SOCS3.
To assess the role of miR-203 in regulating the JAK2/STAT3 signaling pathway, computational analysis (TargetScan v7.1) was performed to predict the potential target genes of miR-203. The results indicated that miR-203 may target sequences in 3'-untranslated region (UTR) of SOCS3 (Fig. 4A) . The 3'-UTR sequence of SOCS3 was then cloned into a luciferase reporter plasmid. A mutant SOCS3 3'-UTR sequence, which included a mutation in the miR-203 binding site, was additionally cloned into the luciferase reporter plasmid (Fig. 4A) . The dual-luciferase reporter assay was performed using HEK293T cells. The results demonstrated that the luciferase activity in HEK293T cells co-transfected with an miR-203 mimic and a luciferase reporter plasmid containing the wild type SOCS3 3'-UTR sequence was significantly reduced when compared with the mimic control (Fig. 4B) . By contest, no significant alterations in luciferase activity were observed HEK293T cells transfected with miR-203 mimic and a luciferase reporter plasmid containing the mutant SOCS3 3'-UTR sequence (Fig. 4B) . In addition, transfection of HaCaT cells with miR-203 mimics was associated with a significant reduction in the mRNA and protein expression levels of SOCS3 (Fig. 4C-E) . These results provide evidence to suggest that SOCS3 may be a direct target of miR-203. 
Repression of miR-203 attenuates IL-17-induced VEGF secretion in
Discussion
The results of the present study demonstrated that miR-203 expression is significantly upregulated in mice and HaCaT cells stimulated with IL-17. In addition, VEGF levels were observed to increase in the ears of IL-17-stimulated mice and in the supernatant of IL-17-treated HaCaT cells. These results suggest that IL-17 may induce VEGF expression, and that miR-203 may be involved in mediating this effect. In addition, the results indicated that inhibition of miR-203 reversed the IL-17-induced increase in VEGF secretion and inhibited the IL-17-induced activation of JAK2/STAT3 signaling. Furthermore, the present study provided evidence to suggest that SOCS3, a repressor of the JAK2/STAT3 signaling pathway, may be a direct target of miR-203. miRNAs are a class of abundant non-coding RNA molecules that modulate mRNA degradation or inhibition of translation by specifically binding to the 3'-UTR of target mRNA sequences (22) (23) (24) . miRNAs serve key roles in the regulation of cell differentiation, growth and death in normal and malignant tissues (25, 26) . miR-203 is a miRNA preferentially expressed in the skin, and is an important regulator of keratinocyte differentiation (18) . miR-203 has been implicated in a number of skin diseases, particularly psoriasis, via regulation of pro-inflammatory cytokines (27, 28) In order to prevent the adverse effects of over-activation, the duration and intensity of JAK/STAT signaling pathway activation is strictly controlled by negative regulators (29) . SOCS proteins are induced by growth factors or cytokines, and regulate the duration and magnitude of inflammatory responses activated by these cytokines via the inhibition of JAK proteins in a negative feedback loop (30) . Previous studies have demonstrated that SOCS1 and SOCS3 proteins are the major regulators of the JAK2/STAT3 signaling pathway (31) (32) (33) . The results of the present study demonstrated that SOCS1 and SOCS3 expression was significantly downregulated in HaCaT cells following stimulation with IL-17. However, only SOCS3 protein expression was upregulated following inhibition of miR-203 in IL-17-treated HaCaT cells. This provides additional evidence to suggest that SOCS3 may be a target of miR-203.
Angiogenesis is an important pathological feature of psoriasis, and the expression of a number of angiogenic mediators, including VEGF, increase during the development of psoriasis (34, 35) . The present study demonstrated that IL-17 induces the expression of VEGF in vitro and in vivo, which is consistent with the results of previous studies (13, 15) . Notably, suppression of miR-203 reversed IL-17-induced VEGF expression in HaCaT cells. These results are consistent with the observed upregulation of SOCS3 expression and the reduction in JAK/STAT signalling pathway activation in the IL-17 signaling process following inhibition of miR-203, which indicated that miR-203 may be involved in mediating IL-17-induced VEGF expression.
In conclusion, the results of the current study suggest that miR-203 may inhibit the expression of SOCS3 by directly binding to the 3'-UTR of SOCS3 and promoting the degradation of the SOCS3 mRNA, thus activating the JAK2/STAT3 signaling pathway and mediating IL-17-induced VEGF secretion. Future studies that aim to investigate the role of miR-203 further, may provide novel insights into its mechanisms of action, as well as identify potential therapeutic strategies for the treatment of psoriasis.
